NumFin

Haemonetics Corporation

Sümbol: HAE

NYSE

91.5

USD

Turuhind täna

  • 36.7000

    P/E suhe

  • 0.2197

    PEG suhe

  • 4.65B

    MRK Cap

  • 0.00%

    DIV tootlus

Haemonetics Corporation (HAE) Finantsaruanded

Download
AastaneQuarterly
LineaarneLog
Diagrammil näete Haemonetics Corporation (HAE) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 565.328 M, mis on 0.065 % gowth. Kogu perioodi keskmine brutokasum on 284.179 M, mis on 0.051 %. Keskmine brutokasumi suhtarv on 0.530 %. Ettevõtte eelmise aasta tulemuse puhaskasv on 1.661 %, mis on võrdne 0.127 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

AastaneQuarterly
10Y20Y30Y40Y

Bilanss

Sukeldudes Haemonetics Corporation fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus 0.040. Käibevara valdkonnas on HAE aruandlusvaluutas 769.722. Märkimisväärne osa neist varadest, täpsemalt 284.466, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust 0.096%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 0, kui neid on, aruandlusvaluutas. See näitab erinevust 0.000% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 754.102 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on -0.010%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud 817.997 aruandlusvaluutas. Selle aspekti aastane muutus on 0.092%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 179.142, varude hind on 259.38 ja firmaväärtus 466.23, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 275.77. Kontovõlad ja lühiajalised võlad on vastavalt 63.93 ja 11.78. Koguvõlg on 765.89, netovõlg on 481.42. Muud lühiajalised kohustused moodustavad 145.89, mis lisandub kohustuste kogusummale 1116.83. Lõpuks hinnatakse viidatud aktsia 0, kui see on olemas.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992

balance-sheet.row.cash-and-short-term-investments

1115.17284.5259.5192.3
137.3
169.4
180.2
139.6
115.1
160.7
192.5
179.1
228.9
196.7
141.6
156.7
133.6
229.2
250.7
185.8
118.1
49.9
67.5
74.5
61.3
56.3
21.8
8.3
13.4
4.2
16.2
10.3
2.9

balance-sheet.row.short-term-investments

7.271.100
0
0
0
0.1
0
0
1.3
0
0
0
0
0
0
0
0
0
0
0
32.6
33
8
12.3
11.9
13.6
0
0
0
0
0

balance-sheet.row.net-receivables

742.12179.1159.4127.6
165.2
185
151.2
152.7
157.1
145.8
165
170.1
135.5
127.2
118.7
113.6
120.3
91.8
86.9
80.7
82.6
77.9
63.7
59.8
59.1
63
58.9
72.2
60.3
63.3
47.5
38.8
33.4

balance-sheet.row.inventory

1138.44259.4293322.6
270.3
194.3
160.8
176.9
186.1
211.1
197.7
183.8
117.2
84.4
80
76.5
65.4
61.8
54.6
53.1
52.2
65.8
67.2
54
59.8
59.8
61.7
55.1
56.7
60
41.3
30.3
30.6

balance-sheet.row.other-current-assets

206.3346.744.151.1
30.8
27.4
29
40.9
28.8
50.4
74.6
64
45.1
40.6
33.5
35.6
40.2
20.8
26.3
24
1.9
2.7
2.8
5.7
29.6
52.2
48.8
32.1
28.5
30.1
25.1
16.1
11.6

balance-sheet.row.total-current-assets

3202.05769.7756693.5
603.6
576.1
521.2
510
487.2
568
629.6
597
526.6
448.8
373.7
382.4
359.4
403.7
418.4
343.6
281.4
223.3
232.8
219.2
209.9
231.3
191.2
167.7
158.9
157.6
130.1
95.5
78.5

balance-sheet.row.property-plant-equipment-net

1241.78310.9258.5217.6
253.4
344
332.2
323.9
337.6
321.9
271.4
257
161.7
155.5
153.3
137.8
116.5
90.8
75.3
69.3
78
84
84.9
83.3
81.6
83
84.2
103.6
86.4
82.1
68.3
56
46.8

balance-sheet.row.goodwill

1952.55466.2467.3466.4
210.7
210.8
211.4
210.8
267.8
334.3
336.8
330.5
115.1
115.4
120.5
56.4
54.2
35
18.5
0
0
0
14.2
14.4
1.8
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

1223.69275.8310.3365.5
133.1
127.7
156.6
177.5
204.5
244.6
271.2
264.4
96.5
101.8
86.1
65.3
64.3
33.9
22.9
44
42
42.3
24.2
15.8
1.8
10.5
10.7
10.3
0
0
9.3
7.6
6.9

balance-sheet.row.goodwill-and-intangible-assets

3176.24742777.5831.9
343.8
338.5
368
388.4
472.3
578.9
607.9
594.9
211.6
217.2
206.6
121.7
118.6
68.8
41.4
44
42
42.3
38.4
30.3
1.8
10.5
10.7
10.3
0
0
9.3
7.6
6.9

balance-sheet.row.long-term-investments

-4.6400-6
-3.9
-4.4
-4
-4
-7.1
-581.9
-609.1
-596.6
-211.6
0
-211.6
0
0
0
0
0
0
0
3.2
0
10.8
24.7
38.6
31
0
0
0
0
0

balance-sheet.row.tax-assets

19.935.24.56
3.9
4.4
4
4
7.1
3
1.2
1.8
0
1.3
4.9
3
9.2
4.5
1.2
0.1
0
3
2.3
1.7
10.7
11.7
9.9
12.8
0
0
0
0
0

balance-sheet.row.other-non-current-assets

473.4310763.276.9
66.3
16.2
16
16.4
20
593.2
619.8
608
222.3
10.5
227.2
4.8
5.2
5
10.2
10.7
5.9
6.7
3.4
10.9
34.3
-4.8
2.1
-1.9
42.5
40.8
23
21.2
12.6

balance-sheet.row.total-non-current-assets

4906.731165.11103.71126.4
663.5
698.6
716.2
728.7
829.9
915.1
891.2
864.9
384
384.4
380.5
267.3
249.5
169.1
128.1
124.1
125.9
136
132.1
126.2
139.2
125.1
145.5
155.8
128.9
122.9
100.6
84.8
66.3

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

8108.791934.81859.71819.9
1267.1
1274.8
1237.3
1238.7
1317.1
1483.1
1520.8
1461.9
910.6
833.3
754.1
649.7
609
572.7
546.5
467.8
407.4
359.2
364.9
345.3
349.1
356.4
336.7
323.5
287.8
280.5
230.7
180.3
144.8

balance-sheet.row.account-payables

279.0763.958.450.3
50.7
63.4
55.3
43
39.7
48.4
53.6
49.9
35.4
28.3
25.6
20.7
19.7
17.2
14.2
11.1
14.2
13.7
12.5
13.3
17.2
10.7
21.7
27.9
16.9
15.6
14.7
13.2
9.1

balance-sheet.row.short-term-debt

52.6611.8214.117
77
27.7
194.3
61
43.5
21.5
45.6
23.1
0.9
0.9
17.1
0.7
6.3
22.2
26.2
26.6
32.8
39
31.4
22.4
32.9
6.6
17.5
19.5
3.4
8.3
4.5
3
8.4

balance-sheet.row.tax-payables

0013.923.7
16.6
12.4
8.3
8.5
5.2
8
10.2
9.2
8.1
6
5.1
2.8
5.3
1.2
10.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

3110.99754.1559.4690.6
305.5
322.5
59.4
253.6
364.5
406.4
392.1
456.9
2.9
4
4.6
5.3
6
6.7
13
19.2
25.4
31.6
40.8
47.3
41.3
52.5
53.6
10
15.2
25.1
9.8
10.6
15.7

Deferred Revenue Non Current

-34.8100-47.5
-14
-226.9
-9.4
-13.7
-23.7
-32.1
-29.7
-29.6
-23.3
0
-13.5
0
0
-4.5
-1.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

170.59---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

641.22145.9137.9159.9
127.7
117.5
109.4
80.7
74.5
96.8
93.8
83
129.8
46.3
114
71.5
46.5
26.9
19.1
50.2
48.8
47.7
40.2
43.7
38.4
51.8
39.2
26.2
26.1
25.2
29.4
22.3
20

balance-sheet.row.total-non-current-liabilities

3574.47865668834.8
395.7
371.1
100.2
287.9
412.4
467.9
463.4
512.9
44.8
38.5
29.9
16.9
17.1
11.1
16.8
24.7
31.8
35.6
44
50.4
54.2
65.4
63.6
24.6
24.4
38.2
21.3
15.1
16.7

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

63.0663.17.270.7
59.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

4589.191116.81110.31088.3
680
606.9
484.9
499.1
597.1
657
681.2
692.7
175.6
147.1
161
109.8
114.8
93.1
104.9
112.6
127.6
136
128.1
129.8
142.7
134.5
142
98.2
70.8
87.3
69.9
53.6
54.2

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

2.030.50.50.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0
0
0
0
0

balance-sheet.row.retained-earnings

1186.18253.2202.4158
78.5
161.4
266.9
289.9
316.2
420.4
433.3
398.2
400.8
373.6
334.6
309.5
302.2
315.8
302.8
233.8
322.3
293
264.6
234.3
230.7
211.8
190.8
215.7
182.7
146.8
113.2
81.7
57

balance-sheet.row.accumulated-other-comprehensive-income-loss

-116.99-30.4-26-29.5
-45.1
-30.4
-19
-32.9
-35
-21.7
1.4
5.4
9.1
9.5
5.9
3.3
4.8
-0.2
-2.8
-0.7
-6.5
-13.5
-16.4
-17.6
-13.1
-19.6
-19.2
-12.4
-74.4
-60.9
-45.1
-34.2
-25.3

balance-sheet.row.other-total-stockholders-equity

2448.37594.7572.5602.7
553.2
536.3
504
482
438.3
427
404.3
365
324.9
302.7
252.3
226.8
186.9
163.8
141.4
121.8
-36.3
-56.6
-11.7
-1.5
-11.5
29.4
22.8
21.7
108.7
107.3
92.7
79.2
58.9

balance-sheet.row.total-stockholders-equity

3519.59818749.4731.7
587.1
667.9
752.4
739.6
720
826.1
839.6
769.2
735.1
686.1
593.1
539.9
494.2
479.6
441.6
355.1
279.7
223.2
236.8
215.5
206.4
221.9
194.7
225.3
217
193.2
160.8
126.7
90.6

balance-sheet.row.total-liabilities-and-stockholders-equity

8108.791934.81859.71819.9
1267.1
1274.8
1237.3
1238.7
1317.1
1483.1
1520.8
1461.9
910.6
833.3
754.1
649.7
609
572.7
546.5
467.8
407.4
359.2
364.9
345.3
349.1
356.4
336.7
323.5
287.8
280.5
230.7
180.3
144.8

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

3519.59818749.4731.7
587.1
667.9
752.4
739.6
720
826.1
839.6
769.2
735.1
686.1
593.1
539.9
494.2
479.6
441.6
355.1
279.7
223.2
236.8
215.5
206.4
221.9
194.7
225.3
217
193.2
160.8
126.7
90.6

balance-sheet.row.total-liabilities-and-total-equity

8108.79---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

2.881.10-6
-3.9
-4.4
-4
-4
-7.1
-581.9
-609.1
-596.6
-211.6
0
-211.6
0
0
0
0
0
0
0
38.6
33
18.8
37
50.5
44.6
0
0
0
0
0

balance-sheet.row.total-debt

3163.65765.9773.6707.6
382.5
350.1
253.7
314.6
408
427.9
437.7
480.1
3.8
4.9
21.7
6
12.4
28.9
39.2
45.8
58.3
70.6
72.1
69.7
74.2
59.1
71.1
29.5
18.6
33.4
14.3
13.6
24.1

balance-sheet.row.net-debt

2048.48481.4514.1515.3
245.2
180.8
73.5
175.1
292.9
267.2
245.2
301
-225.1
-191.8
-119.9
-150.7
-121.2
-200.4
-211.5
-140
-59.9
20.7
37.2
28.3
12.9
2.8
49.3
21.2
5.2
29.2
-1.9
3.3
21.2

Rahavoogude aruanne

Haemonetics Corporation finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab 1.150 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 7.02, mis tähistab -1.370 erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli -143788000.000. See on 0.665 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 93.31, 1.61, -9.63, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte -7.02 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui -15.74, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992

cash-flows.row.net-income

126.57115.443.479.5
76.5
55
45.6
-26.3
-55.6
16.9
35.1
38.8
0.8
0.7
58.4
59.3
52
49.1
69.1
39.6
29.3
28.4
30
7.2
19
21.1
-24.8
33
35.9
33.6
31.5
24.8
18

cash-flows.row.depreciation-and-amortization

93.4393.397.784.3
110.3
109.4
89.2
89.7
90
86.1
81.7
65.5
50
48.1
43.2
36.5
31.2
27.5
25.1
27.6
30.1
28.4
25.6
24.5
24.9
24.6
22.9
12.3
13.1
13.7
10.7
8.5
7

cash-flows.row.deferred-income-tax

22.114.85-19.9
-7
13.4
-5.8
-6.8
-1
4.2
-0.2
0.6
5.9
5.8
2.6
1.6
-0.9
0
-0.3
4
1.3
4
-0.7
2.1
-1.7
-7.3
-0.3
3.6
-3.2
0.9
0
3.4
0.4

cash-flows.row.stock-based-compensation

27.9725.624.425.5
20.5
17.2
13
9.2
6.9
14.1
13.1
11
9.3
10.8
10.3
10.2
0.2
0
0
0
0
0
0
0
0
-14.7
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

-79.4125.5-15.2-59.7
-84.6
-62.8
76.5
-1
-20.1
-3.5
0.2
-41.4
-15.5
-19
4.1
5.1
-10.7
-8.4
-14.4
-0.5
14.1
-14.9
-25.7
5.9
4.1
10.1
-15.4
-22.1
8.9
-32.7
-13.6
-0.8
-6.4

cash-flows.row.account-receivables

-27.79-24.4-3544.1
18.9
-38.1
5.1
3.2
-10.3
8.8
6.2
-38.1
-10.5
-3.9
4.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-44.4730.824.3-38.9
-84.7
-39.3
14.4
-1.6
12.8
-16.9
-12.7
-18.7
-32.5
-2.6
-1.7
-11.2
-2.9
-8.5
-5.5
-4.7
9.3
-5.5
-18.3
6.4
-1.8
2.5
-14.7
-0.9
-0.2
-13.5
-10.6
1.1
-6.7

cash-flows.row.account-payables

18.8439.87.6-56.4
-17.3
17.7
0
0
0
12.7
3.6
21.6
22.5
-17
12.5
17.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

-25.98-20.6-12.2-8.5
-1.4
-3.1
57
-2.6
-22.6
4.6
6.8
15.4
27.6
-12.5
1.4
16.3
-7.8
0.1
-8.9
4.2
4.9
-9.5
-7.4
-0.5
5.9
7.6
-0.7
-21.2
9.1
-19.2
-3
-1.9
0.3

cash-flows.row.other-non-cash-items

6.618.516.9-0.9
42.5
27.1
1.8
94.9
101.6
9.4
9.5
10.6
65.7
77.7
12.1
3.7
6.1
15.4
6.1
0.5
-0.3
-2.2
3.1
21.2
7.2
-14.8
38
-0.1
0.1
0.1
-1.6
0
-0.2

cash-flows.row.net-cash-provided-by-operating-activities

197.28000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-68.53-110.2-96.5-37
-48.8
-119
-74.8
-76.1
-102.4
-122.2
-73.6
-62.2
-53.2
-46.7
-56.3
-56.4
-57.8
-41.5
-36.8
-17.5
-13.9
-13.5
-21.6
-30.5
-23.3
-22.5
-20.4
-32
-19.7
-24.9
-22.9
-17.6
-11.4

cash-flows.row.acquisitions-net

-243.78-28.1-390.2
-25.2
2.8
9
0
-3
0
-32.7
-535.2
0
-6.4
-77.8
-6
-46.9
-32.5
0
-5
0
0
-10.5
-26.6
0
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

15.81-33.200
0
0
0
0
0
0
0
-1
0
0
0
0
0
0
0
-49.8
0
-11.7
-69.9
-47.4
0
0
0
0
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

23.73000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
88.5
0
44.3
66.5
49.7
0
0
0
0
0
0
0
0
0

cash-flows.row.other-investing-activites

-54.571.621.8
16.8
0
2.8
0
-101.8
0
-73.2
-60.2
1
1.5
1.8
2.4
1.8
2.8
4.7
3.3
6
0.4
2.2
4.6
-6.8
29.2
-26.6
0
-6.2
-5.2
-1.3
0
-7

cash-flows.row.net-cash-used-for-investing-activites

-327.34-143.8-86.3-425.4
-57.2
-116.1
-63
-73.3
-104.8
-121.8
-105.8
-596.4
-52.2
-51.6
-132.3
-60
-102.8
-71.1
-32.1
19.4
-7.9
19.5
-33.2
-50.1
-30.1
6.7
-47
-32
-25.9
-30.1
-24.2
-17.6
-18.4

cash-flows.row.debt-repayment

-337-9.6-17.5-81.9
-13.1
-266.9
-61
-93.4
-20
-9.6
-38
-0.9
-0.8
0
-0.8
-6.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

7.2776.5-3.2
12
13.4
0
0
0
0
0
0
3.7
0
0
0
17.2
14.9
15.1
26.2
18.1
4.8
13.5
14.7
8.5
6.4
3.1
4.7
2.9
1.8
2.4
1.2
7.6

cash-flows.row.common-stock-repurchased

-5.88-7500
-175
-160
-100
0
-61
-39
0
-50
-50
-50
-40
-60
-75
-40
0
0
0
-50.2
-26.9
-4.7
-39.7
0
-5.6
-15.8
-8.9
-15.7
-0.1
0
-2

cash-flows.row.dividends-paid

0-700
-12
-13.4
0
0
0
0
0
0
-15.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-4.3

cash-flows.row.other-financing-activites

441.31-15.7-4.8452.6
56.9
376.2
40.3
33
18.4
15.5
17.3
512.7
16.6
31.9
26.8
35.5
-15.5
-10.4
-3
-11.7
-17.3
-3.6
4
-5
13.4
-11.9
42.6
13.9
-13
16.1
-0.5
-12
-0.5

cash-flows.row.net-cash-used-provided-by-financing-activities

100.06-100.4-15.7367.5
-131.2
-50.6
-120.6
-60.4
-62.6
-33.2
-20.7
461.9
-30.5
-18.1
-14
-30.7
-73.2
-35.6
12.1
14.5
0.7
-49
-9.3
5
-17.8
-5.5
40.1
2.8
-19
2.2
1.8
-10.8
0.8

cash-flows.row.effect-of-forex-changes-on-cash

-0.02-3.9-34.2
-1.9
-3.3
3.9
-1.6
0
-4.1
0.4
-0.3
-0.5
1.3
0.5
-2.5
2.7
1.7
-0.8
1.2
0.8
0.8
0.1
-0.3
-0.5
-0.4
0
-2.6
-0.7
0.3
1.3
-0.2
0

cash-flows.row.net-change-in-cash

-30.022567.255
-32
-10.8
40.6
24.4
-45.5
-31.8
13.3
-49.7
32.2
55.1
-15.2
23.2
-95.7
-21.4
64.9
106.3
68.2
15
-10.3
15.5
5
34.5
13.5
-5.1
9.2
-12
5.9
7.3
1.2

cash-flows.row.cash-at-end-of-period

1115.17284.5259.5192.3
137.3
169.4
180.2
139.6
115.1
160.7
192.5
179.1
228.9
196.7
141.6
156.7
133.6
229.2
250.7
185.8
118.1
49.9
34.9
41.4
61.3
56.3
21.8
8.3
13.4
4.2
16.2
10.2
2.9

cash-flows.row.cash-at-beginning-of-period

1145.19259.5192.3137.3
169.4
180.2
139.6
115.1
160.7
192.5
179.1
228.9
196.7
141.6
156.7
133.6
229.2
250.7
185.8
79.5
49.9
34.9
45.2
25.9
56.3
21.8
8.3
13.4
4.2
16.2
10.3
2.9
1.7

cash-flows.row.operating-cash-flow

197.28273.1172.3108.8
158.2
159.3
220.3
159.7
121.9
127.2
139.5
85.1
115.3
123.5
130.7
116.4
77.7
83.6
85.6
71.2
74.6
43.7
32.2
61
53.5
33.7
20.4
26.7
54.8
15.6
27
35.9
18.8

cash-flows.row.capital-expenditure

-68.53-110.2-96.5-37
-48.8
-119
-74.8
-76.1
-102.4
-122.2
-73.6
-62.2
-53.2
-46.7
-56.3
-56.4
-57.8
-41.5
-36.8
-17.5
-13.9
-13.5
-21.6
-30.5
-23.3
-22.5
-20.4
-32
-19.7
-24.9
-22.9
-17.6
-11.4

cash-flows.row.free-cash-flow

128.75162.975.871.8
109.5
40.3
145.6
83.6
19.5
5
65.9
22.9
62.1
76.8
74.4
60
19.9
42.1
48.8
53.7
60.7
30.1
10.6
30.5
30.1
11.2
0
-5.3
35.1
-9.3
4.1
18.3
7.4

Kasumiaruande rida

Haemonetics Corporation tulud muutusid võrreldes eelmise perioodiga 0.177%. HAE brutokasum on teatatud 615.1. Ettevõtte tegevuskulud on 459.06, mille muutus võrreldes eelmise aastaga on 5.829%. Kulud amortisatsioonikulud on 93.31, mis on 0.052% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 459.06, mis näitab 5.829% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab 0.932% kasvu võrreldes eelmise aastaga. Tegevustulu on 156.03, mis näitab 0.932% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on 1.661%. Eelmise aasta puhaskasum oli 115.4.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000199919981997199619951994199319921991

income-statement-row.row.total-revenue

1270.181168.7993.2870.5
988.5
967.6
903.9
886.1
909.7
910.4
938.5
892
727.8
676.7
645.4
597.9
516.4
449.6
419.7
383.6
364.2
337
320
293.9
277.9
282.1
285.8
309.8
278.2
262.4
248.4
216.3
176.4
157.3

income-statement-row.row.cost-of-revenue

598.29553.6487.7472.6
504
550
492
507.6
503.8
476
470.1
463.9
358.6
321.5
307.9
289.7
258.7
222.3
199.2
185.7
192.1
182.3
165.1
126.9
121.7
124
127.1
137.8
110.5
103.9
94.2
88.8
78.5
0

income-statement-row.row.gross-profit

671.89615.1505.5397.8
484.5
417.5
411.9
378.5
405.9
434.4
468.4
428.1
369.2
355.2
337.5
308.2
257.7
227.3
220.5
197.9
172.1
154.7
154.8
166.9
156.2
158.1
158.7
172
167.7
158.5
154.2
127.5
97.9
157.3

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

54.22---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

90.18---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

7.2---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

4032.347.432.8
50.6
0
0
-8.1
87.7
5.4
1.7
-6.5
0
-1.9
13.3
0
0
-5.5
-26.4
-0.1
0
0
0
4.6
24.9
24.6
22.9
12.3
13.1
13.7
10.7
8.5
7
0

income-statement-row.row.operating-expenses

491.28459.1433.8339.9
330.6
334
355.8
339.3
369.5
393.9
421
367.4
282.1
244.7
240.9
222.6
187.4
155.5
121.5
137.9
126.2
117.2
108.4
110.4
122.6
126.4
127.7
123.6
113.4
106.1
102.4
85.7
68
0

income-statement-row.row.cost-and-expenses

941.4459.1921.5812.5
834.5
884
847.8
846.9
873.3
869.8
891.2
831.3
640.7
566.1
548.8
512.3
446.2
377.8
320.7
323.7
318.4
299.5
273.5
237.3
244.3
250.4
254.8
261.4
223.9
210
196.6
174.5
146.5
0

income-statement-row.row.interest-income

6.11135.89.4
13.5
9.9
0
0
0
0
0
0
0
0.4
0.4
2
5.4
7.9
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

9.1214.617.116.8
16.2
9.9
4.5
8.1
9.5
9.4
10.9
-54.7
-54.6
0
0.7
0.1
-9
0.1
-37
0
-0.9
-3.5
13.6
59.4
13.1
-5.9
74.9
-6.3
-4.1
-2.1
-1.7
1.6
1.6
0

income-statement-row.row.selling-and-marketing-expenses

7.2---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-17.07-14.6-17.114.9
-66.8
-9.9
8
-58.6
-80.3
-5.4
-1.7
-6.5
2.3
-0.8
-15
-2.5
2
-0.6
29.2
0.1
1
2.4
-7.9
-20.2
-6.9
5.1
-23
4
3.2
2
2.7
0.2
0.6
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

4032.347.432.8
50.6
0
0
-8.1
87.7
5.4
1.7
-6.5
0
-1.9
13.3
0
0
-5.5
-26.4
-0.1
0
0
0
4.6
24.9
24.6
22.9
12.3
13.1
13.7
10.7
8.5
7
0

income-statement-row.row.total-operating-expenses

-17.07-14.6-17.114.9
-66.8
-9.9
8
-58.6
-80.3
-5.4
-1.7
-6.5
2.3
-0.8
-15
-2.5
2
-0.6
29.2
0.1
1
2.4
-7.9
-20.2
-6.9
5.1
-23
4
3.2
2
2.7
0.2
0.6
0

income-statement-row.row.interest-expense

9.1214.617.116.8
16.2
9.9
4.5
8.1
9.5
9.4
10.9
-54.7
-54.6
0
0.7
0.1
-9
0.1
-37
0
-0.9
-3.5
13.6
59.4
13.1
-5.9
74.9
-6.3
-4.1
-2.1
-1.7
1.6
1.6
0

income-statement-row.row.depreciation-and-amortization

77.6493.388.784.3
110.3
109.4
89.2
89.7
90
86.1
81.7
65.5
50
48.1
43.2
36.5
31.2
27.5
25.1
27.6
30.1
28.4
25.6
24.5
24.9
24.6
22.9
12.3
13.1
13.7
10.7
8.5
7
0

income-statement-row.row.ebitda-caps

258.25---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

170.1915680.858
153.9
83.5
56.2
-19.4
-44
40.5
47.3
56.4
88.8
110.5
83.3
85.6
70.3
62.7
99
59.9
45.9
37.5
36.4
13.4
33.6
31.7
31
48.4
54.3
52.4
51.8
41.8
29.9
157.3

income-statement-row.row.income-before-tax

161.08141.463.672.9
87.2
73.6
59.6
-27.5
-53.5
31.2
36.4
49.9
89.5
110.1
81.3
85
77.3
72.3
106.9
59.8
45.8
38.6
38.5
17.3
27.3
32.6
4.5
50.7
55.2
52.5
50.8
40
27.7
0

income-statement-row.row.income-tax-expense

34.52620.3-6.6
10.6
18.6
14.1
-1.2
2.2
14.3
1.3
11.1
22.6
30.1
22.9
25.7
25.3
23.2
37.8
20.2
16.5
10.2
10.8
10.1
8.5
11.4
3.9
17.7
19.3
18.9
19.3
15.2
9.7
0

income-statement-row.row.net-income

126.57115.443.479.5
76.5
55
45.6
-26.3
-55.6
16.9
35.1
38.8
66.9
80
58.4
59.3
52
49.1
69.1
39.6
29.3
28.4
30
7.2
19
21.1
-24.8
33
35.9
33.6
31.5
24.8
18
0
Sarnased aktsiad
Sind võib huvitada ka:
CNVVF
ConvaTec Group Plc.
3.25 USD
PNK
300753.SZ
Jiangsu Apon Medical Technology Co., Ltd..
12.05 CNY
SHZ
YPHDF
Ypsomed Holding AG.
405 USD
PNK
INFU
InfuSystem Holdings, Inc..
7.62 USD
AMEX
688289.SS
Sansure Biotech Inc..
20.53 CNY
SHH
7780.T
Menicon Co., Ltd..
1516.5 JPY
JPX
ALC.SW
Alcon Inc..
71.82 CHF
SIX
TARSONS.NS
Tarsons Products Limited.
470 INR
NSE
SDI.AX
SDI Limited.
0.86 AUD
ASX
OMIC
Singular Genomics Systems, Inc..
0.3975 USD
NASDAQ
FPH.AX
Fisher & Paykel Healthcare Corporation Limited.
23.66 AUD
ASX

Korduma kippuv küsimus

Mis on Haemonetics Corporation (HAE) koguvara?

Haemonetics Corporation (HAE) koguvara on 1934825000.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on 654433000.000.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.529.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on 2.536.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on 0.100.

Mis on ettevõtte kogutulu?

Kogutulu on 0.134.

Mis on Haemonetics Corporation (HAE) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on 115401000.000.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 765886000.000.

Mis on tegevuskulude arv?

Tegevuskulud on 459064000.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 193978000.000.